Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients
| Autor: | Christian Jacquelinet, Yves Deugnier, Annick Ruffault, Dominique Guyader, Patrice Andre, Eveline Boucher, Bruno Turlin, Pierre Brissot, Romain Moirand, H. Jouanolle |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male HBsAg medicine.medical_specialty Hepatitis C virus medicine.medical_treatment Biopsy Molecular Sequence Data Hepacivirus Interferon alpha-2 medicine.disease_cause Gastroenterology Liver disease Clinical Protocols Interferon Internal medicine medicine Humans Hepatitis Chemotherapy Hepatology biology Base Sequence business.industry Ursodeoxycholic Acid Interferon-alpha Alanine Transaminase gamma-Glutamyltransferase Middle Aged medicine.disease Combined Modality Therapy Hepatitis C Ursodeoxycholic acid Recombinant Proteins Alanine transaminase Immunology Chronic Disease biology.protein RNA Viral Female business medicine.drug Follow-Up Studies |
| Zdroj: | Hepatology (Baltimore, Md.). 21(2) |
| ISSN: | 0270-9139 |
| Popis: | Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase levels in patients with chronic hepatitis, we undertook a prospective controlled randomized trial of IFN (group I) versus IFN plus UDCA (group II) in 80 patients with chronic hepatitis C. IFN was administered in both groups for 6 months (3 to 5 million units [MU] three times a week), and in group II UDCA (10 mg/kg/d) was administered with IFN and then alone for 3 additional months. Response to therapy was defined as the normalization of alanine transaminase (ALT) levels. The results showed that 6 months after cessation of IFN, 59% of responders had relapsed in group I but only 27% had relapsed in group II (P = .03). There was no difference between the two groups for the initial (month 6) and the late (months 15 and 18) response rates to IFN. There was no virological effect or significant histological improvement attributable to the addition of UDCA to IFN treatment. In conclusion, the results of this study show that the addition of UDCA to IFN therapy significantly prolongs the period for which serum ALT remain, within the normal range after discontinuation of IFN. Further studies would be required to determine whether UDCA has any potential for long-term amelioration of the histological severity of liver disease caused by hepatitis C virus (HCV) infection, and, therefore, whether it could be advocated as an adjunct to antiviral therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text